论文部分内容阅读
目的:观察肺表面活性物质治疗新生儿呼吸窘迫综合征(NRDS)的临床疗效。方法:选取2013年5月至2014年11月我院收治的57例NRDS患儿,随机分为治疗组32例和观察组25例,治疗组使用肺表面活性物质(珂立苏)联合鼻塞持续气道正压呼吸治疗,观察组使用机械通气治疗,观察两组患儿治疗效果及临床特征。结果:两组治疗前血气分析及呼吸机参数比较差异无统计学意义(P>0.05)。治疗后2 h治疗组Pa O2为(65.09±5.52),观察组为(58.56±5.23);OI治疗组为(5.83±1.96),观察组(6.13±1.15);a/A PO2治疗组(0.361±0.092),观察组(0.163±0.062)。呼吸机参数在治疗后Fi O2治疗组为(0.34±0.09),观察组为(0.44±0.14);PEEP治疗组为(4.09±1.16),观察组为(4.28±1.11)。治疗组患儿治疗后肺氧合功能比观察组改善程度更为显著,两组比较差异有统计学意义(P<0.05)。两组治疗前及治疗48 h后X线胸片结果显示治疗组复查24例,有18例恢复正常,6例好转;对照组复查19例,5例恢复正常,10例好转,4例无改变。治疗组临床治愈率为81.25%,对照组为60.00%。结论:肺表面活性物质治疗NRDS能迅速有效的改善肺部氧合功能和肺通气,使用方便,治疗效果值得肯定。
Objective: To observe the clinical efficacy of pulmonary surfactant in the treatment of neonatal respiratory distress syndrome (NRDS). Methods: 57 children with NRDS admitted to our hospital from May 2013 to November 2014 were randomly divided into treatment group (n = 32) and observation group (n = 25). The treatment group was treated with pulmonary surfactant (Ke Li Su) combined with nasal obstruction Positive airway pressure breathing treatment, the observation group using mechanical ventilation treatment, observation of two groups of children with treatment and clinical features. Results: There was no significant difference in blood gas analysis and ventilator parameters between the two groups before treatment (P> 0.05). PaO2 was (65.09 ± 5.52) in treatment group and (58.56 ± 5.23) in observation group and (5.83 ± 1.96) in observation group (6.13 ± 1.15) and 0.361 ± 0.092), observation group (0.163 ± 0.062). Ventilator parameters were (0.34 ± 0.09) in Fi O2 treatment group and (0.44 ± 0.14) in treatment group; (4.09 ± 1.16) in PEEP treatment group and (4.28 ± 1.11) in observation group. After treatment, the oxygenation function of the treatment group was more significant than that of the observation group. The difference between the two groups was statistically significant (P <0.05). The results of X-ray before treatment and 48 hours after treatment showed that in the treatment group, 24 cases were rechecked, 18 cases returned to normal and 6 cases improved. In the control group, 19 cases were rechecked, 5 cases returned to normal, 10 cases improved and 4 cases did not change . The clinical cure rate was 81.25% in the treatment group and 60.00% in the control group. CONCLUSIONS: Pulmonary surfactant treatment of NRDS can rapidly and effectively improve lung oxygenation function and pulmonary ventilation. It is easy to use and the treatment effect is worthy of recognition.